Health editor Michael Smith on CSL’s remarkable story, why investors have fallen out of love with the healthcare giant and what Trump has to do with it. CSL was run like a bureaucracy until 1990 when ...

CSL showcases Seqirus revenue growth and market leadership at its 2025 Capital Markets Day in Chicago. CSL's Seqirus division has grown revenue from $751 million in FY16 to a projected $2 billion in ...

A strike is when more than 25 per cent of shareholders are against a company proposal, in this case executive pay, paving the way for a second ballot on whether to spill the board. Shareholders have ...

CSL Ltd. plunged to the lowest in almost seven years after Australia’s biggest drugmaker postponed plans to spin off its vaccines business, as falling US flu immunizations deepen concern over a ...

CSL (ASX:CSL) has attracted fresh attention after its Broadmeadows plasma fractionation facility in Australia was named the Overall Winner of the 2025 Facility of the Year Award by the International ...

(Reuters) -Australian biotech CSL said on Tuesday it no longer expects to complete the spin-off of its vaccine division in fiscal 2026, citing heightened volatility in the U.S. influenza vaccine ...

A rare 2023 BMW M4 CSL with only 1,600 miles is up for sale on Bring a Trailer. This lightweight, high-performance coupe looks almost new and demands attention. The Ultimate Driving Machine never ...

CSL's shares have declined over 25% this year due to slower margin recovery, tariff concerns, and Seqirus demerger uncertainty, challenging investor confidence. Despite these issues, analysts like ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The Australian biotechnology ...

CSL has moved quickly to spend some of the money freed up by recent cuts, securing an option to buy the phase 3-ready blood clotting specialist VarmX in return for $117 million upfront. Last month, ...

SYDNEY--Australian pharmaceutical company CSL said on Tuesday that it has agreed to a deal to advance a blood coagulation treatment and potentially acquire its closely held Dutch developer. CSL said ...

CSL will invest up to $760 million in Dutch biotech VarmX, marking the healthcare giant’s first major investment since it announced 3000 job cuts and plans to scale back its global research and ...